Tyra Biosciences, Inc. (NASDAQ:TYRA) Short Interest Update

Tyra Biosciences, Inc. (NASDAQ:TYRA) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,760,000 shares, a decrease of 20.0% from the October 15th total of 2,200,000 shares. Currently, 6.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 294,700 shares, the short-interest ratio is presently 6.0 days.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TYRA shares. HC Wainwright reduced their price objective on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Monday. Piper Sandler started coverage on Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Finally, Oppenheimer raised their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $31.00.

Tyra Biosciences Stock Up 3.8 %

Shares of Tyra Biosciences stock opened at $16.34 on Friday. Tyra Biosciences has a 12-month low of $10.60 and a 12-month high of $29.60. The stock has a market capitalization of $826.80 million, a P/E ratio of -10.15 and a beta of 1.08. The stock has a 50 day moving average price of $21.51 and a two-hundred day moving average price of $19.98.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Sell-side analysts anticipate that Tyra Biosciences will post -1.56 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 27,493 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $16.56, for a total value of $455,284.08. Following the completion of the sale, the director now directly owns 458,506 shares of the company’s stock, valued at approximately $7,592,859.36. This represents a 5.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alan Fuhrman purchased 9,500 shares of Tyra Biosciences stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $16.00 per share, with a total value of $152,000.00. Following the completion of the transaction, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at $205,584. This represents a 283.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 101,050 shares of company stock worth $2,235,492 in the last 90 days. Corporate insiders own 15.40% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Tyra Biosciences by 18.6% in the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after acquiring an additional 140,833 shares during the last quarter. American Century Companies Inc. boosted its holdings in Tyra Biosciences by 582.9% in the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after purchasing an additional 145,346 shares during the period. Perceptive Advisors LLC grew its position in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after purchasing an additional 338,208 shares during the last quarter. Ensign Peak Advisors Inc acquired a new position in shares of Tyra Biosciences during the second quarter valued at about $3,047,000. Finally, SG Americas Securities LLC acquired a new stake in Tyra Biosciences during the third quarter worth about $311,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.